Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 4/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 9/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19954591 | 0.85 | MAPK1 (0.35) | MAP3K12TLR8TLR7TLR9MAPK1 | |
| SCHEMBL21023573 | 0.85 | BTK (0.38) | BTKMAP3K12JAK1TLR8TLR7 | |
| SCHEMBL18161157 | 0.84 | TLR8 (0.39) | BTKMAP3K12JAK1TLR8TLR7 | |
| SCHEMBL21023768 | 0.83 | POLB (0.33) | MAP3K12TLR8TLR7TLR9 | |
| SCHEMBL19954595 | 0.81 | IL1B (0.35) | MAP3K12TLR8TLR7TLR9 | |
| SCHEMBL19954655 | 0.80 | GAA (0.36) | TLR8TLR7TLR9GSK3B | |
| SCHEMBL19954637 | 0.80 | ALDH1A1 (0.34) | MAP3K12 | |
| SCHEMBL19954664 | 0.78 | MAPK1 (0.39) | TLR8TLR7TLR9MAPK1 | |
| SCHEMBL19954579 | 0.78 | NR3C2 (0.36) | TLR8TLR7TLR9 | |
| SCHEMBL19954593 | 0.78 | GAA (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392350-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180222867-A1 | N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION | 2018-08-09 | — | — | US | disclosed |
| US-9914706-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392350-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | ATP5F1A, ATP5ME, ATP5F1D | BTK 2815/4885MAP3K12 1341/4885JAK1 4236/4885 |
| US-20180222867-A1 | N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1D | BTK 2815/4885MAP3K12 1341/4885JAK1 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.